

10-23-06

IFW

Express Mail Label No.: EV 869858387 US

Date of Deposit: October 19, 2006

Attorney Docket No.: 23239-538



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Wilson, et al.
SERIAL NUMBER : 10/664,610 EXAMINER : Humphrey, Louise
Wang Zhiying
FILING DATE : September 16, 2003 ART UNIT : 1648
FOR : PROPHYLACTIC AND THERAPEUTIC HIV APTAMERS

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Transmitted herewith for filing in the present application are the following documents:

1. Corrected Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (6 page), in duplicate; and
3. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 23239-538. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529
Jennifer A. Karnakis, Reg. No. 53,097
Attorneys for Applicant
c/o MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Date: October 19, 2006

Express Mail Label No.: EV 869858387 US

Date of Deposit: October 19, 2006

Attorney Docket No.: 23239-538

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Wilson, et al.

SERIAL NUMBER : 10/664,610

EXAMINER : Humphrey, Louise
Wang Zhiying

FILING DATE : September 16, 2003

ART UNIT : 1648

FOR : PROPHYLACTIC AND THERAPEUTIC HIV APTAMERS

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

CORRECTED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In an Office Action mailed on September 25, 2006, the Examiner indicated that the non-patent references cited in the Information Disclosure Statements filed on March 29, 2006 and May 22, 2006 were not considered because they were not compliant with 37 C.F.R. 1.98(b)(5). Applicants hereby submit the attached modified Forms PTO-1449 in compliance with 37 C.F.R. 1.98(b)(5). The attached modified Forms PTO-1449 are corrected versions of the Information Disclosure Statements submitted to the U.S. Patent and Trademark Office on March 29, 2006 and May 22, 2006.

Although these corrected Supplemental Information Disclosure Statements are being filed after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311, Applicants believe no fee or certification is due, as the previously filed Information Disclosure Statements were submitted before the mailing date of a first Office Action based on the merits in the above-identified case. Copies of the non-considered references are not provided as they were previously submitted to the Office with the prior Information Disclosure Statements mailed March 29, 2006 and May 22, 2006.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has

APPLICANTS: **Wilson, et al.**
U.S.S.N.: **10/664,610**


been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 23239-538.

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529
Jennifer A. Karnakis, Reg. No. 53,097
Attorneys for Applicant
c/o MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Date: October 19, 2006

TRA 2211239v.1

Please type a plus sign (+) in this box



Modified Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/664,610
Filing Date	September 16, 2003
First Named Inventor	Wilson
Group Art Unit	1648
Examiner Name	Humphrey, Louise Wang Zhiying
Attorney Docket Number	23239-538

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C2	Araki et al., (1998) "Allosteric regulation of a ribozyme activity through ligand-induced conformational change", <i>Nucl. Acids Res.</i> , 26(14):3379-3384
	C3	Sayer et al., (2002) "Structural characterization of a 2'F-RNA aptamer that binds a HIV-1 SU glycoprotein, gp120", <i>Biochem. Biophys. Res. Commun.</i> , 293:924-931
	C4	Supplementary Partial European Search Report for EP 03 75 2557, mailed February 15, 2006.

Copies of the references are not provided as they were previously submitted to the U.S. Patent Office with a prior Information Disclosure Statement mailed March 29, 2006.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: EV 869858387 US
Date of Deposit: October 19, 2006

Page 1 of 5
Attorney Docket: 23239-538

Please type a plus sign (+) in this box



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/664,610
	Filing Date	September 16, 2003
	First Named Inventor	Wilson
	Group Art Unit	1648
	Examiner Name	Humphrey, Louise Wang Zhiying
	Attorney Docket Number	23239-538

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C5	Andrake (1988) "DNA polymerase of bacteriophage T4 is an autogenous translational repressor", Proc. Natl. Acad. Sci. USA 85:7942-7946
	C6	Barnett et al., (2001) "The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region", J. Virol. 75:5526-5540
	C7	Belshe et al., (1994) "HIV infection in vaccinated volunteers", JAMA. 272: 431
	C8	Burton (1997) "A vaccine for HIV type 1: the antibody perspective", Proc Natl Acad Sci U S A. 94: 10018-10023
	C9	Carey et al., (1983) "Sequence-specific interaction of R17 coat protein with its ribonucleic acid binding site", Biochem. 22(11):2601-2610
	C10	Chen et al. (1994) "Selection of high-affinity RNA ligands to reverse transcriptase: inhibition of cDNA synthesis and Rnase H activity", Biochem. 33:8746-8756
	C11	Cohen et al. (1969) "Interactions of hormonal steroids with nucleic acids: a specific requirement for guanine", Proc. Natl. Acad. Sci. USA 63:458-464
	C12	Cohen J. (1994) "U.S. panel votes to delay real-world vaccine trials", Science 264: 1839
	C13	Conrad et al., (1996) "In vitro selection of nucleic acid aptamers that bind proteins", Meth. Enzymol. 267: 336-367
	C14	Cormier et al., (2000) "Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120", PNAS 97: 5762-5767
	C15	Cummins et al., (1995) "Characterization of fully 2'-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity", Nucl. Acids Res. 23: 2019-2024

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C16	Davis et al. (1996) "Identifying consensus patterns and secondary structure in SELEX sequence sets", Meth. Enzymol. 267(18): 302-314
	C17	Dehouck et al., (1996) "Blood-brain barrier <i>in vitro</i> - rapid evaluation of strategies for achieving drug targeting to the central nervous system", Biol. Physiol. Blood Brain Barrier, Couraud and Scherman eds., Chapter 23, pp. 143-146
	C18	Doranz et al., (1999) "Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events", J. Virol. 73: 10346-10358
	C19	Dougan et al., (2000) "Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood", Nucl. Med. Biol. 27: 289-297
	C20	Ellington & Szostak (1990) Abstracts of papers presented at the 1990 meeting on RNA Processing, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, Pg. 84
	C21	Emini et al., (1992) "Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody", Nature 355: 728-730
	C22	Evans et al., (2001) "QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans", Vaccine 19: 2080-2091
	C23	Fitzwater et al., (1996) "A SELEX primer", Meth. Enzymol. 267:275-301
	C24	Fouts et al., (2002) "Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques", PNAS 99:11842-11847
	C25	Gaschen et al., (2002) "Diversity considerations in HIV-1 vaccine selection", Science 296:2354-2360
	C26	Gath et al., (1996) "The blood-CSF barrier <i>in vitro</i> ", Biol. Physiol. Blood Brain Barrier, Couraud and Scherman eds., Chapter 25, pp. 153-158
	C27	Graham BS. (2002) "Clinical Trials of HIV vaccines", Annu. Rev. Med. 53: 207-221
	C28	Green et al., (1995) "Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor", Chem. Biol. 2:683-695
	C29	Jellinek et al., (1994) "Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor", Biochem. 33:10450-10456
	C30	Jellinek et al., (1995) "Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor", Biochem. 34(36):11363-11372
	C31	Joyce & Inoue (1989) "A novel technique for the rapid preparation of mutant RNAs", Nucl. Acids Res. 17:711-722
	C32	Joyce (1989) "Amplification, mutation and selection of catalytic RNA", Gene 82:83-87
	C33	Kacian et al. (1972) "A replicating RNA molecule suitable for a detailed analysis of extracellular evolution and replication", Proc. Natl. Acad. Sci. USA 69:3038-3042
	C34	Kadonaga et al. (1986) "Affinity purification of sequence-specific DNA binding proteins", Proc. Natl. Acad. Sci. USA 83:5889-5893
	C35	Kahn et al., (1994) "Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1 _{SF2} gp120 submit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers", J. Infect. Dis. 170: 1288-1291
	C36	Kalams et al., (2000) HIV Vaccines 2000: Prospects and Challenges. In "The Human Immunodeficiency Virus", Princeton University Press, Princeton, N.J. pp 481-509
	C37	Kellogg et al., (1994) "Taqstart antibody TM : 'hot start' PCR facilitated by a neutralizing monoclonal antibody directed against taq DNA polymerase" BioTechniques 16:1134-1137
	C38	Kinzel & Vogelstein (1989) "Whole genome PCR: application to the identification of sequences bound by gene regulatory proteins", Nucl. Acids Res. 17:3645-3653
	C39	Kinzel et al. (1990) "The GLI gene encodes a nuclear protein which binds specific sequences in the human genome", Mol. Cell. Biol. 10:634-642

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C40	Kowalski et al., (1987) "Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1", Science 237: 1351-1355
	C41	Kramer et al. (1974) "Evolution <i>in vitro</i> : sequence and phenotype of a mutant RNA resistant to ethidium bromide", J. Mol. Biol. 89:719-736
	C42	Kraus et al., (1998) "Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4 ⁺ T lymphocyte function", J. Immunol. 160:5209-5212
	C43	Kwong et al., (1998) "Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody", Nature 393:648-659
	C44	Kwong et al., (2002) "HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites", Nature 420:678-682
	C45	Langlois et al., (1998) "Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus", J. Virol. 72:6950-6955
	C46	Leonard et al., (1990) "Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in chinese hamster ovary cells" J. Biol. Chem. 265: 10373-10382
	C47	Lestienne et al. (1983) "Inhibition of human leucocyte elastase by polynucleotides" Biochimie 65:49-52
	C48	Levisohn & Spiegelman (1968) "The cloning of a self-replicating RNA molecule", PNAS USA 60:866-872
	C49	Levisohn & Spiegelman (1969) "Further extracellular Darwinian experiments with replicating RNA molecules: diverse variants isolated under different selective conditions", PNAS USA 63:805-811
	C50	Lu et al., (1995) "A trimeric structural domain of the HIV-1 transmembrane glycoprotein", Nat. Struct. Biol. 2:1075-1082
	C51	Ma and Ptashne (1987) "A new class of yeast transcriptional activators", Cell 51:113-119
	C52	Maniatis (1982) Molecular Cloning: a Laboratory Manual, Cold Spring Harbor, NY pg.118
	C53	Maniatis et al. (1987) "Regulation of inducible and tissue-specific gene expression", Science 236:1237-1245
	C54	Martin et al., (2003) "Rational design of a CD4 mimic that inhibits HIV-1 entry and expose cryptic neutralization Epitopes", Nat. Biotechnol. 21:71-76
	C55	Mascola et al., (1996) "Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1", J. Infect. Dis. 173:340-348
	C56	McGaughey et al., (2003) "HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb", Biochemistry 42:3214-3223
	C57	Miele et al., (1983) "Autocatalytic replication of a recombinant RNA", J. Mol. Biol. 171:281-295
	C58	Mills et al., (1967) "An extracellular darwinian experiment with a self-duplicating nucleic acid molecule", Proc. Natl. Acad. Sci. USA 58:217-220
	C59	Mills et al., (1973) "Complete nucleotide sequence of a replicating RNA molecule", Science 180:916-927
	C60	Min et al., (1988) "Search for the optimal sequence of the ribosome binding site by random oligonucleotide-directed mutagenesis", Nucl. Acids Res. 16:5075-5088
	C61	Moore et al., (1988) "Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1", AIDS Res. Hum. Retroviruses 4(5):369-379
	C62	Moulard et al., (2002) "Broadly cross-reactive HIV-1-neutralizing human monoclonal fab selected for binding to gp120-CD4-CCR5 complexes", Proc. Natl. Acad. Sci. U S A 99:6913-6918
	C63	Muesing et al. (1985) "Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus", Nature 313:450-458
	C64	Nixon et al., (1999) "Molecular tracking of an human immunodeficiency virus nef specific Cytotoxic t-cell clone shows persistence of clone-specific t-cell receptor DNA but not mRNA

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		following early combination antiretroviral therapy”, Immunol. Lett. 66(1-3):219-228
	C65	Oliphant & Struhl (1987) “The use of random-sequence oligonucleotides for determining consensus sequences”, Meth. Enzymol. 155:568-582
	C66	Oliphant & Struhl (1988) “Defining the consensus sequences of E.coli promoter elements by random selection”, Nucl. Acids Res. 16:7673-7683
	C67	Oliphant et al. (1986) “Cloning of random-sequence oligodeoxynucleotides”, Gene 44:177-183
	C68	Oliphant et al. (1989) “Defining the sequence specificity of DNA-binding proteins by selecting binding sites from random-sequence oligonucleotides: analysis of yeast GCN4 protein”, Mol. Cell. Biol. 9:2944-2949
	C69	Orgel (1979) “Selection <i>in vitro</i> ”, Proc. R. Soc. Lon. B 205:435-442
	C70	Ou et al. (1988) “DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells”, Science 239:295-297
	C71	Pieken et al., (1991) “Kinetic characterization of ribonuclease-resistant 2 prime - modified hammerhead ribozymes”, Science 253:314-317
	C72	Poignard et al., (2001) “GP120: biologic aspects of structural features”, Annu. Rev. Immunol. 19:253-274
	C73	Prince et al., (1991) “Prevention of HIV infection by passive immunization with HIV immunoglobulin”, AIDS Res. Hum. Retroviruses 7:971-973
	C74	Profy et al., (1990) “Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual”, J. Immunol. 144:4641-4647
	C75	Putkonen et al., (1991) “Prevention of HIV-2 and SIV _{sm} infection by passive immunization in cynomolgus monkeys”, Nature 352:436-438
	C76	Richman et al., (2003) “Rapid evolution of the neutralizing antibody response to HIV type 1 infection”, PNAS 100:4144-4149
	C77	Rizzuto et al., (1998) “A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding”, Science 280:1949-1953
	C78	Robertson & Joyce (1990) “Selection <i>in vitro</i> of an RNA enzyme that specifically cleaves single-stranded DNA”, Nature 344:467-468
	C79	Romaniuk et al. (1987) “RNA binding site of R17 coat protein”, Biochem. 26(6):1563-1568
	C80	Ruckman et al., (1998) “2'-fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF ₁₆₅)”, J. Biol. Chem. 273:20556-20567
	C81	Saffhill et al. (1970) “ <i>In vitro</i> selection of bacteriophage Q β ribonucleic acid variants resistant to ethidium bromide”, J. Mol. Biol. 51:531-539
	C82	Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, NY, Section 8.9-8.10
	C83	Sattentau et al., (1991) “Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding”, J. Exp. Med. 174:407-415.
	C84	Sattentau et al., (1993) “Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding”, J. Virol. 67:7383-7393
	C85	Singleton et al., Dictionary of Microbiol. & Molec. Biol., Wiley & Sons, New York, NY, 2nd ed. p. 493
	C86	Sood et al., (1977) “A rapid and convenient synthesis of poly-thymidylic acid by the modified triester approach”, Nucl. Acids Res. 4(8):2757-2765
	C87	Soukup and Breaker (1999) “Design of allosteric hammerhead ribozymes activated by ligand-induced structure stabilization”, Structure 7(8):783-791
	C88	Sproat et al., (1991) “New synthetic routes to synthons suitable for 2'-O-allyl oligoribonucleotide assembly”, Nucl. Acids Res. 19(4):733-738
	C89	Starcich et al., (1986) “Identification and characterization of conserved and variable regions in the

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		envelope gene of HTLV-III/LAV, the retrovirus of AIDS", Cell 45:637-648
	C90	Sullivan et al., (1998) "Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies", J. Virol. 72:6332-6338
	C91	Szostak, Structure and Activity of Ribozymes, Redesigning the Molecules of Life, (SA Benner ed.) Springer-Verlag Berlin Heidelberg, pp. 87-113 (1988)
	C92	Tanchou et al. (1994) "Monoclonal antibody-mediated inhibition of RNA binding and annealing activities of HIV type 1 nucleocapsid protein", Aids Research and Human Retroviruses 10:983-993
	C93	Thali et al., (1993) "Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization Epitopes exposed upon gp120-CD4 binding", J. Virol. 67:3978-3988
	C94	Thiesen & Bach (1990) "Target detection assay (TDA): a versatile procedure to determine DNA binding sites as demonstrated on SP1 protein", Nucl. Acids Res. 18:3203-3209
	C95	Trkola et al., (1996) "CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5", Nature 384:184-187
	C96	Trkola et al., (1996) "Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1", J. Virol. 70:1100-1108
	C97	Tucker et al., (1999) "Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys", J. Chromatography B. 732:203-212
	C98	Tuerck and Gold (1990) "Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase", Science 249(4968):505-510
	C99	Tyagi et al., (1996) "Molecular beacons: probes that fluoresce upon hybridization", Nat. Biotechnol. 14:303-308
	C100	Uhlenbeck et al. (1983) "Interaction of R17 coat protein with its RNA binding site for translational repression", J. Biomol. Struct. Dynamics 1:539-552
	C101	Watanabe M. (2003) "Skeptical scientists skewer vaxgen statistics", Nat. Med. 9: 376
	C102	Watson et al., (1987) Mol. Biol. Gene, Benjamin/Cummings Publishing Co., Inc. California, pp. 267,295,323,361,394,396,397 and 405
	C103	Wei et al., (2003) "Antibody neutralization and escape by HIV-1", Nature 422:307-312
	C104	Wu et al., (1996) "CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5", Nature 384:179-183
	C105	Wu et al., (1997) "CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, <i>in vitro</i> ", J. Exp. Med. 185:1681-1691
	C106	Yamamoto and Kumar (2000) "Molecular beacon aptamer fluoresces in the presence of tat protein of HIV-1", Genes to Cells 5:389-396
	C107	Zhang et al., (1999) "Conformational changes of gp120 in Epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic", Biochemistry. 38:9405-9416
	C108	Zhang et al., (2001) "Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4", Biochemistry. 40:1662-1670

Copies of the references are not provided as they were previously submitted to the U.S. Patent Office with a prior Information Disclosure Statement mailed May 22, 2006.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.